The history of research and development of EGFR-TKI and ALK inhibitors in lung cancer treatment reveals that finding clear driver genes for tumors is of great significance for developing new drugs, selecting the right treatment population and ensuring the therapeutic efficacy of targeted drugs. Here, EGFR is linked to lung carcinoma.